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Poor prognosis breast cancers are treated with cytotoxic chemotherapy, but often without 
any guidance from therapy predictive markers since universally-accepted markers are not 
currently available. Treatment failure, in the form of recurrences, is relatively common. We 
aimed to identify chemotherapy predictive markers and resistance pathways in breast 
cancer. Our hypothesis was that tumour cells remaining after neoadjuvant chemotherapy 
(NAC) contain somatic variants causing therapy resistance, while variants present pre-NAC 
but lost post-NAC cause sensitivity.  
 
Whole exome sequencing was performed on matched pre- and post-NAC cancer cells, 
which were isolated by laser microdissection, from 6 cancer cases, and somatic variants 
selected for or against by NAC were identified. Somatic variant diversity was significantly 
reduced after therapy (p<0.05). MUC17 variants were identified in 3 tumours and were 
selected against by NAC in each case, while PCNX1 variants were identified in 2 tumours 
and were selected for in both cases, implicating the function of these genes in defining 
chemoresponse. In vitro knock-down of MUC17 or PCNX1 was associated with significantly 
increased or decreased chemotherapy sensitivity respectively (p<0.05), further supporting 
their roles in chemotherapy response. Expression was tested for predictive value in two 
independent cohorts of chemotherapy-treated breast cancers (n=53, n=303). Kaplan-Meier 
analyses revealed that low MUC17 expression was significantly associated with longer 
survival after chemotherapy, while low PCNX1 was significantly associated with reduced 
survival. 
 
We concluded that therapy-driven selection of somatic variants allows identification of 
chemotherapy response genes. With respect to MUC17 and PCNX1, therapy-driven 
selection acting on somatic variants, in vitro knock-down data concerning drug sensitivity, 
and survival analysis of expression levels in patient cohorts all define the genes as 






Breast cancer is the most common malignancy in women and the second most common 
overall, and is estimated to cause more than 600,000 deaths annually worldwide (1). Breast 
cancer has been at the forefront of new cancer treatments, exemplified by the range of 
molecularly targeted therapies, for example therapies targeting estrogen receptor (ER) or 
her2, and more recently CDK4/6 or PARP (2). Despite these advances, traditional cytotoxic 
chemotherapy is still used in treatment of more than a third of primary breast cancer patients 
(3), and the vast majority of metastatic patients. Included in this are poorer prognosis 
classifications of primary breast cancer, such larger and more advanced ER-positive 
cancers, triple negative cancers (negative for ER, her2 and progesterone receptor) (4), 
which lack suitable alternative systemic therapies, and her2-positive subtypes, which are 
treated with her2 targeted agents combined with chemotherapy (5). Cytotoxic chemotherapy 
gives improved outcomes overall (6), but treatment failure is relatively common, as 
evidenced by recurrences after primary disease, or progression and eventual death in the 
metastatic setting. Unfortunately, understanding of chemoresistance pathways is 
incomplete, and most patients are not currently stratified using markers to cytotoxic 
chemotherapy agents to which they are most likely to respond, or spared chemotherapy if 
good responses to any are unlikely. An exception may be use of the multigene assay 
Oncotype DX, which has gained some traction for prediction of chemotherapy benefit in 
some patient groups in some countries, although evidence supporting this use is not 
universally-accepted (7). Therefore, there is an urgent need to identify resistance pathways 
and use these insights to develop and validate predictive markers, allowing improved 
response rates through stratification, and to identify resistance-related therapeutic targets, 
which could allow inhibition of resistance thereby eliciting responses in otherwise resistant 
cancers (8). 
 
Chemotherapy for primary breast cancer is increasingly given in the neoadjuvant setting for 
at least two reasons. Firstly, tumours can be down-staged, facilitating less radical surgical 
resections (9). Secondly, it provides an opportunity to assess tumour responses to specific 
agents using longitudinal imaging, allowing switching to alternative agents if initial responses 
are inadequate (10). Neoadjuvant chemotherapy (NAC) also provides a powerful research 
opportunity since matched primary tumour samples from before (diagnostic biopsies) and 
after therapy (resections) may be available. With respect to chemotherapy response, a 
relevant hypothesis is that tumour cells that remain post-NAC have characteristics 
associated with therapy resistance, while characteristics lost from tumour cells in the 
matched pre-NAC sample are associated with sensitivity; therefore, comparative analysis of 
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these matched samples can give insights into both resistance and sensitivity (11). Based on 
this hypothesis, investigators have examined expression pre-NAC and post-NAC and 
identified individual molecules such as bFGF (12), families of molecules such as xenobiotic 
drug pumps (13), or pathway-level gene expression changes (14) that were associated with 
relative resistance. We have taken a genomics approach using these matched tissues. We 
have determined and compared sub-clonal somatic mutational profiles throughout the 
exome of purified cancer cells in a cohort of breast tumours pre- and post-NAC, to our 
knowledge the first such study. Using these data, we aimed to identify genes that host 
somatic variants selected for or against by NAC; these genes would represent candidate 
mediators of chemoresponse whether through selection of mutations, as in our screen, or 
through other pathways acting on gene expression more generally, as testing in our 
validation cohorts. In this way, we expected to gain understanding of molecular pathways 
that define chemoresponses, and to provide potential predictive markers and 
chemosensitising therapeutic targets.  
 
 
Materials and methods 
 
Ethics and clinical samples  
Ethical approval was obtained from Leeds (East) REC (#06/Q1206/180). This study used 
formalin-fixed paraffin-embedded (FFPE) tissue held by Leeds Teaching Hospitals NHS 
Trust (Leeds, UK). Samples were from 3 cohorts of female patients diagnosed with primary 
breast cancer within the trust. 1) 6 patients treated with NAC, after diagnoses post-2013. 
Cases were selected based on: partial responses to epirubicin/cyclophosphamide (defined 
by longitudinal imaging); ER-positive tumours (defined by clinical ER assessment); presence 
of sufficient cancer cells in diagnostic biopsies and resections (assessed using hematoxylin 
and eosin stained sections). Samples were available for matched pre-NAC biopsies, post-
NAC resections, and normal tissue from resections >1cm outside tumour margins. 2) 53 
NAC-treated patients, diagnosed 1/1/2005 to 30/4/2013; a subset of a published cohort (15). 
Exclusion criteria were patients who did not undergo surgery, had metastatic disease, lacked 
imaging follow-up, or had complete pathological responses. Duplicate 0.6mm cores 
representing post-NAC tissue were available in TissueMicroarrays (TMAs). 3) 303 patients 
treated with adjuvant chemotherapy, diagnosed 1/2006 to 12/2010. Exclusion criteria were 
patients who received any neoadjuvant therapy, had metastatic disease, or had second 
breast cancers subsequent to initial diagnosis/treatment prior to 2006. TMAs containing 
treatment-naïve resection tissue (three independent 0.6mm cores per case) were assembled 
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using manual tissue microarrayers (Beecher Instruments, WI, USA), after representative 
tissue areas (central and peripheral when possible) were identified microscopically on whole 
tissue blocks/sections by consultant histopathologists (ETV, AMH). 
 
Laser capture microdissection (LCM) and DNA extraction 
LCM to purify cancer cells was performed broadly as described previously (16); further 
details are included in Supplementary Methods. For normal tissue blocks, cellular tissue was 
identified macroscopically and was manually macro-dissected. QIAamp MinElute Columns 
DNA FFPE Tissue or AllPrep DNA/RNA FFPE Kits (Qiagen; Dusseldorf, Germany) were 
used to extract DNA, which was quantified using Quant-iT PicoGreen dsDNA kits 
(ThermoFisher; MA, USA) and quality assessed using the Agilent 2200 TapeStation (Agilent 
Technologies; CA, USA) (all following the manufactures’ protocols). 
 
Library preparation, sequencing and data analysis 
Whole exome sequencing libraries were prepared from 0.2-1.2μg DNA using NEBNext Ultra 
DNA Library Prep Kits (New England Biolabs; MA, USA) and SureSelectXT reagents 
(Agilent Technologies; CA, USA) (see Supplementary Methods for protocols). Indexed 
libraries were pooled and sequenced on the HiSeq 3000 (Illumina; CA, USA), with pair end 
reads (2x150bp). Sequence data have been deposited at the European Genome-phenome 
Archive, under accession number EGAS00001003626 (https://ega-archive.org). Exome data 
were analysed to identify somatic single nucleotide/small indel variants by Edinburgh 
Genomics Laboratory (Edinburgh, UK), as described in Supplementary Methods.  
 
Cell culture, transfection, and chemoresponse assays 
MCF7 cells were purchased (ATCC; Manassas, USA) and cultured in DMEM, 10% FCS 
(ThermoFisher; MA, USA), 95% air/5% CO2 at 37°C. Cell line identity was confirmed (STR 
profiles, Leeds Genomics Service, UK) and cultures were consistently mycoplasma negative 
(MycoAlert, Lonza; Basal, Switzerland). ON-TARGETplus siRNA-SMARTpools (Dharmacon; 
CO, USA) were used to perform targeted/control knock-downs (sequences in 
Supplementary Methods). Cells were seeded at 10,000 (96-well plate) or 500,000 cells/well 
(6-well plate) and then incubated overnight. 25nM or 50nM final siRNAs concentrations were 
prepared in serum-free medium (OptiMEM, ThermoFisher; MA, USA) and transfection 
complexes prepared using DharmaFECT formula 1 (Dharmacon; CO, USA) following the 
manufacturer’s protocols. Serum-free complexes were added to cells with 4 volumes of 
complete fresh medium and 24h later medium was removed and replaced with further fresh 
medium. Epirubicin hydrochloride (Sigma Aldrich, MO, USA) was prepared as a 10mM stock 
solution in water, and was diluted to working concentrations in medium. MTT (3-(4,5-
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Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assays were performed as described 
previously (17). For colony forming assays, cells were transfected and epirubicin-treated 
(24h), before cells were harvested in trypsin-EDTA (ThermoFisher; MA, USA) and replated 
in fresh (epirubicin-free) medium at 500 or 1000 cells (depending on expected survival to 
ensure colony numbers were countable) per 10cm culture dish (Corning; MA, USA). Cells 
were cultured undisturbed for 14 days. Medium was removed and cells were fixed in 3ml 
acetic acid/methanol 1:7 (vol/vol) for 5min. Colonies were stained with 0.5% crystal violet 
(Sigma Aldrich, MO, USA) for 1min. Colonies were counted macroscopically, regarding >50 
cells as a colony. To validate colony counting reproducibility, 10 plates with different colony 
numbers were scored independently by authors WSAA and LMA; concordance between 
scorers was very high (Spearman’s rank r=0.948 p<0.0001). Intracellular epirubicin uptake 
assays were performed using flow cytometry on the Attune Acoustic focusing cytometer 
(ThermoFisher; MA, USA) with fluorescent detection in BL-3 as described previously (18).  
 
Quantitative (q)PCR  
RNA was extracted using ReliaPrep RNA cell Minipreps (Promega; WI, USA) and quantified 
using the NanoDrop 2000/2000c Spectrophotometer (ThermoFisher; MA, USA), according 
to manufacturers’ protocols. High-capacity cDNA RT kits (ThermoFisher; MA, USA) were 
used for reverse transcription following the manufacturer’s protocols. qPCR was performed 
using Taqman protocols/assays: MUC17 (#Hs00959753s1), PCNX1 (#Hs00900449m1), 
ABCB1 (#Hs00184500m1), ABCC1 (#Hs01561483m1), ABCG2 (#Hs01053790m1), RPL19 
(#Hs02338565), ACTB (#Hs99999903m1) (ThermoFisher; MA, USA). Reactions were 
prepared in technical duplicates/triplicates and assayed in a QuantStudio 5 instrument 
(Applied Biosystems, ThermoFisher; MA, USA) using standard mode and cycling conditions. 
QuantStudio Design and Analysis Software (ThermoFisher; MA, USA) was used to calculate 
CTs and average of replicates was taken for each sample. The 2−ΔΔCT method was 




All steps were at room temperature unless otherwise stated. TMA blocks were sectioned at 
3 or 5μm onto Superfrost Plus slides (ThermoFisher; MA, USA). Slides were dewaxed 
through xylene, brought through absolute ethanol, and then into running water. Antigen 
retrieval was performed using 10mM citric acid buffer, pH 6.0 and microwave heating 
(10min, high power). Endogenous peroxidase was blocked with 10min in 0.3% hydrogen 
peroxide. Slides were washed in running water and rinsed with Tris-Buffered Saline (TBS). 
Slides were transferred to humidified chambers and 100μl of antibody diluent reagent 
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solution (ThermoFisher; MA, USA) was added for 5min. After that, 1:250 anti-MUC17 rabbit 
polyclonal antibody (#ab122184, Abcam; Cambridge, UK) or 1:500 anti-PCNX1 rabbit 
polyclonal antibody (#ab220503, Abcam; Cambridge, UK) was added and incubated 
overnight (4°C) or 2h respectively. Negative controls were antibody diluent solution alone. 
Slides were washed with TBS-T (0.1% Tween20, Sigma Aldrich; MO, USA) twice and TBS 
twice. Slides were treated with 100μl SignalStain Boost IHC detection reagent (HRP, Rabbit) 
(Cell Signaling Technology; MA, USA) for 30min, and were washed with TBS-T and TBS as 
previously. 100μl SignalStain DAB substrate working solution (Cell Signaling Technology; 
MA, USA) was added for 5min and slides were washed in running water. Slides were 
counterstained with Mayer’s Haematoxylin, washed in running water, incubated in Scott’s 
water (1min), and washed again in running water. Finally, slides were dehydrated through 
absolute ethanol and xylene and mounted under coverslips in DPX (Sigma Aldrich; MO, 
USA). Slides were digitally scanned (Aperio; CA, USA), and were scored on-line. Scoring 
protocols were devised in consultation with AMH (consultant breast histopathologist) to 
record the variation seen across the cohorts. Cytoplasmic MUC17 was scored for intensity 
only (it was expressed similarly in all tumour cells of each case, therefore positive cell 
proportion was not informative): 0, no staining; 1, weak staining; 2, moderate staining; 3, 
strong staining. PCNX1 was scored based on intensity of nuclear staining (scores between 
0-3 as above) and proportion of tumour cells showing positive nuclear staining (0, 0%; 1, 1-
5%; 2, 6-25; 3, 26-75%, 4, >75%), with final scores being the sum (0-7). All cores were 
scored by author WSAA, and to validate scoring reproducibility, 10% of cores were scored 
additionally and independently by AMH; concordance between scorers was assessed as 
near perfect or substantial (Kappa scores of 0.8 for MUC17 and 0.7 for PCNX) (20).  
 
Statistical analyses 
Statistical analyses were performed as described in figure legends, using GraphPad Prism 
(v7) for Mann-Whitney tests, paired Student’s T tests, or 2-way ANOVAs. ROC curves, 
Spearman’s rank correlation analyses, and Kaplan-Meier survival analyses were performed 





NAC is associated with an overall reduction in genetic diversity in breast tumours 
Our first aim was to perform whole exome sequencing on tumour cells pre- and post-NAC 
from a small group of primary breast cancers. We focused on ER-positive cancers – a 
strategy we found to be essential since typically this cancer type is relatively resistant to 
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NAC as compared to other breast cancer subtypes (21) and therefore numbers of tumour 
cells after treatment would be increased and post-treatment genomic analysis would be 
possible. We also minimised variation within our cohort in clinico-pathological features, 
therapeutic regimen, and treatment response in an effort to increase the likelihood of 
identifying resistance or sensitivity pathways in common between individuals. Consequently, 
6 patients were selected with tumours that had partial therapy responses as defined by 
clinical MRI monitoring during therapy to an epirubicin/cyclophosphamide regimen, and were 
ER-positive, her2-negative, and mainly ductal carcinomas of no special type (Table S1). 
Tissue was available pre- and post-NAC and, importantly, cancer cells were isolated by LCM 
(Fig S1) to allow extraction of tumour DNA with minimal contamination by normal stromal 
DNA, thereby maximising our ability to detect somatic variants in relatively rare clones. 
Matched normal DNA was also extracted from normal tissues for each individual. DNA was 
subjected to whole exome sequencing.  
 
Quality control analyses of exome data are shown in Table S2, demonstrating some 
variation in quality as expected particularly in the context that some samples were prepared 
by LCM from small, FFPE biopsies therefore input DNA was limiting. Somatic variants in 
cancer samples were identified and their numbers, along with overlaps between matched 
pre- and post-NAC samples, are shown in Venn diagrams (Fig 1), while the full list of 
variants is available in Table S3. Our analysis provided sensitivity to detect mutant variants 
represented in very rare clones, for example the rarest variant detected had a mutant allele 
frequency of only 0.012. Mutations in PIKC3 and TP53, the genes most commonly mutated 
in breast cancer, were detected in 1 and 2 cases respectively, which was in line with 
expectations within a small cohort (reportedly present in 42% and 15% of ER-positive cases 
overall (22)). Numbers of variants showed substantial variation between samples (45-1434) 
as previously reported in breast cancer, which is regarded as genetically heterogeneous 
(23); nevertheless, some consistent observations can be made. There were large and 
significant differences in mutational load between pre- and post-NAC, with pre-NAC samples 
containing a mean of 434 variants, while post-NAC this was reduced to 148 (paired T test, 
p=0.03). Also, overlaps between somatic variants in matched pre- and post-NAC samples 
was relatively small, with a mean number of variants shared between the matched samples 
of 34 (range 3-141), representing only 13.1% of the totals from pre-NAC samples and 19.1% 
from post-NAC. Both these observations are in line with those in related previous studies 
(24,25)  We concluded that NAC causes substantial changes in the clonal composition of 
breast cancers, with an overall reduction in somatic variant diversity.  
 
 9 
MUC17 or PCNX1 variants are changed in representation post-NAC in multiple 
patients  
We selected variants in genes MUC17 and PCNX1 for further analysis, on the basis of 
identification in multiple patients, consistency in representation in either pre- or post-NAC 
samples (ie consistency in potential selection by NAC), and predictions of functional 
consequences of variants (focusing on coding changes with at least one example of a strong 
prediction of a damaging phenotype). MUC17 was found to have 3 different somatic 
missense single nucleotide variants in 3 separate patients (50% of the cohort). All these 
variants were identified in pre-NAC samples, while MUC17 somatic variants were not 
present in the matched (or indeed any) post-NAC samples. This distribution was compatible 
with the hypothesis that these MUC17 variants are associated with relative chemotherapy 
sensitivity, since post-NAC they had apparently been eliminated. PCNX1 was found to have 
2 different somatic deletions leading to frame-shifts in 2 separate patients (33% of the 
cohort); both deletions were identified in post-NAC samples but were not present in any pre-
NAC samples, a distribution compatible with the hypothesis that the deletions are associated 
with relative chemotherapy resistance. Further details of the variants, the sequencing 
evidence for them, and their predicted consequences are shown in Table 1. MUC17 variants 
cause missense changes to the encoded protein within its extra-cellular domain that were 
defined as being of ‘moderate’ predicted functional impact. Variant Thr3809Met is of 
particular note, since this is immediately adjacent to the transmembrane EGF-like domain of 
the protein. This EGF-like domain is a region of likely functional importance, since it is 
believed to direct EGFR mediated oncogenic signalling (26), supporting the potential 
negative functional impact of the variant. PCNX1 variants cause frame-shifts at residues 564 
or 623 (of 2341 residues), which are predicted to cause premature termination, and may 
induce nonsense-mediated decay of transcripts (27). In both cases, the likely predicted 
effect is a loss of gene function. 
 
MUC17 and PCNX1 mediate response to chemotherapy in MCF7 cells in vitro 
Next, we aimed to use a cell line model to screen MUC17 and PCNX1 for roles in defining 
chemoresponse, in order to support further potential analyses in clinical cohorts; it is worth 
emphasising that the intention here was to provide a further in vitro screening step only, 
whereas subsequent separate analyses would provide the essential, robust, clinical 
validation of any impact of candidate proteins on chemotherapy response to meet our key 
aim of defining therapy predictive markers. Our strategy was to mimic the loss of function 
mutations using siRNA-mediated knock-down, and to assess impact on chemosensitivity in 
vitro; therefore, we needed a cell line that was representative of the same breast cancer 
subtype as the cancers used for sequencing (ER-positive/her2-negative), and we needed to 
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ensure that MUC17 and PCNX1 were wild-type and expressed (therefore potentially 
functional). MCF7 cells were identified as suitable from their receptor expression status (28), 
and MUC17 and PCNX1 expression/sequence data available from the Cancer Cell Line 
Encyclopaedia (https://portals.broadinstitute.org/ccle).   
 
First, we assessed whether siRNA could successfully manipulate MUC17 or PCNX1 
expression. MCF7 cells were transfected with siRNAs targeted against MUC17 or PCNX1, 
or with non-targeted control siRNAs, and qPCR was used to quantify relative expression 
post-transfection (Fig 2A). Both gene products were successfully and significantly targeted 
for up to 96h; knock-down efficiency was up to 99% (PCNX1 48h). Knock-down was also 
confirmed at the protein level (Fig S2). Then, we assessed sensitivities of cells after these 
transfections to the chemotherapeutic epirubicin, which was the key component of the 
regimen used in the clinical cases that were sequenced above. MCF7 cells were transfected 
with MUC17 or PCNX1 targeted siRNA, or with non-targeted control as before, and then 
after 24h, cells were treated with a range of epirubicin doses. MTT assays were performed 
after 24, 48 and 72h of drug treatment (Fig 2B); note that these times represent 48, 72 and 
96h post-transfection, time-points at which suitable knock-down is maintained (Fig 2A). As 
expected, cells showed reduced survival after epirubicin treatment that was dose- and time-
dependent. No significant differences were noted when comparing sensitivities of control 
and targeted siRNA cells at 24 or 48h for either gene, or at 72h for PCNX1. However, at 72h 
the MUC17 siRNA treated cells demonstrated significantly increased sensitivity to epirubicin 
(two-way ANOVA, p=0.0018). In accordance with this, a trend for increased sensitivity after 
MUC17 knock-down was also seen at 24h and 48h. Next, we assessed epirubicin-sensitivity 
after these transfections using clonogenic survival assays, in which cells were treated with 
drug and then cultured in drug-free medium for 2 weeks to allow assessment of proportions 
of cells that retained long-term proliferative potential. This assay is sensitive to terminal 
cellular damage that does not cause immediate cell death, and is consequently more 
reflective of some aspects of clinical cancer treatments. Cells were transfected and treated 
with epirubicin, and their potential to grow into viable colonies was assessed (Fig 2C). 
Targeting MUC17 with siRNA significantly reduced survival after epirubicin treatment, 
whereas, targeting PCNX1 significantly increased survival (Mann Whitney tests for individual 
doses, p<0.05, and two-way ANOVA to assess overall chemo-response, p<0.0001). We 
concluded that reduced MUC17 expression caused relative epirubicin sensitisation, a 
conclusion supported the elimination of cells with presumed loss of function MUC17 variants 
by epirubicin-based therapy in the initial patient group. By contrast, we concluded that 
reduced PCNX1 expression caused relative epirubicin resistance, a conclusion supported by 
the survival of cells with loss of function PCNX1 variants in patients after therapy. 
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We also investigated potential mechanisms by which MUC17 or PCNX1 impact on 
chemosensitivity. We noted that cells transfected with siRNA targeted against MUC17 
expressed significantly decreased levels of xenobiotic pumps ABCB1 (encoding P-
glycoprotein) and ABCC1 (encoding MRP-1), while those transfected with siRNA targeted 
against PCNX1 expressed significantly increased levels of ABCG2 (encoding BCRP) (Fig 
S3A). These pumps have been implicated as mediators of chemoresistance by actively 
exporting many chemotherapeutics (29). Accordingly, transfection with siRNA against 
MUC17 was associated with increased cellular loading of epirubicin while transfection with 
siRNA against PCNX1 was associated with reduced loading (Fig S3B). 
 
MUC17 and PCNX1 expression predicts survival after chemotherapy 
Having determined that levels of MUC17 and PCNX1 potentially impact on epirubicin 
efficacy in vitro and in patients, we were interested to assess whether expression levels of 
these proteins could predict chemotherapy response in larger cohorts. Our hypothesis was 
not that somatic mutations impact on overall expression frequently, since our own data 
demonstrated that the mutations when present were in minority clones of the tumours (Table 
1); rather, we wished to test whether the genes we had implicated in chemoresistance 
through selection acting on somatic mutations had wider chemoresistance roles through 
differential expression. Therefore, we assembled two further independent sets of breast 
cancer samples from patients who had been treated with chemotherapy in either the 
neoadjuvant (n=53) or the adjuvant setting (n=303). Clinico-pathological data concerning 
patients and their tumours are shown in Table 2. It is worth noting that both cohorts included 
a variety of breast cancer subtypes that were treated with various chemotherapy regimens, 
unlike the work above that focused only on ER-positive disease and epirubicin; this is 
because we were keen to examine whether any effects we identified were limited to specific 
subgroups or were generally applicable to all breast cancers. Breast cancer samples were 
collected into Tissue MicroArrays (TMAs), comprising up to 3 separate cores from each 
tumour. MUC17 or PCNX1 expression was assessed using immunohistochemistry and was 
scored semi-quantitatively on scales of 0-3 for MUC17 or 0-7 for PCNX1 (Fig 3A). Mean 
scores from multiple cores were calculated to give scores for individual cases (Fig 3B). 
Scores did not show significant correlations with the standard breast cancer prognostic 
markers, estrogen receptor status (positive/negative), tumour grade (1, 2, 3), lymph nodes 
metastasis (positive/negative) or molecular subtype (triple negative vs others) (Table S4). 
 
Kaplan-Meier survival analyses were performed to determine whether expression of MUC17 
or PCNX1 was significantly related to either disease free survival (DFS) or disease specific 
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survival (DSS). Cut-offs were applied to dichotomise patients into two groups based on low 
or high expression of each marker. These cut-offs were defined objectively using receiver 
operator curve analyses (30) to give the best balance between sensitivity and specificity for 
prediction of clinical outcome (see Table S5). For the neoadjuvant cohort (Fig 4A), MUC17 
showed a significant relationship with DFS, in which patients with low MUC17 expression 
survived considerably longer than those with high levels (by a mean of 823 days; log rank 
p<0.02). This relationship was not significant for DSS, and PCNX1 did not show significant 
relationships with survival.  
 
In the adjuvant cohort (Fig 4B), which is substantially larger therefore statistically more 
powerful, further significant findings were made. MUC17 again showed a significant 
relationship with DFS, with low MUC17 expression defining improved survival (by 208 days; 
p<0.03), and this was also reflected in significantly improved disease specific survival (by 
159 days; p<0.04). PCNX1 expression was again not significantly related to survival, 
however the plots showed separation between low and high expression groups that was in 
accordance with expectations from our data concerning selection of somatic variants by 
NAC and in vitro sensitivity, specifically that low expression could be associated with relative 
resistance and therefore poor survival. These trends encouraged us to investigate the 
markers in combination in this adjuvant cohort; therefore, we examined survival in groups 
with high MUC17 and low PCNX1 (both potentially indicative of worse survival), or low 
MUC17 and high PCNX1 (both potentially indicative of improved survival). Significant 
differences in both DFS and DSS were revealed in the directions expected when either of 
these groups was compared to the remainder of the cohort (Fig 4C; p=0.008 to p=0.022), 
showing greater significance and larger differences in mean survival between the two groups 
than with either marker alone. Patients with high MUC17 and low PCNX1 had shorter DFS 
and DSS by 353 and 365 days respectively, while those with low MUC17 and high PCNX1 
had longer DFS and DSS by 297 and 544 days. We also performed subgroup analyses, 
testing associations in groups with different receptor expressions, focusing on the ER-
positive, ER-negative, her2-positive or triple negative groups, or chemotherapy regimens, 
focusing on treatment with anthracyclines with or without taxanes. This was particularly 
relevant since our initial work was solely in the context of ER-positive/her2-negative disease 
with anthracyclines and no taxanes. Low MUC17 was a significant predictor of improved 
survival in both ER-positive (DFS p=0.03; DSS p<0.02) and ER-negative disease (DFS 
p<0.03), and also in her2-positive (DFS p<0.03) and triple negative (DFS p<0.04) groups 
(Fig S4A), suggesting that the marker has value across subtypes. PCNX1 also 
demonstrated significant relationships with survival in both ER-positive (DFS p<0.05) and 
ER-negative disease (DFS p<0.05), and in the triple negative group (DFS p<0.05), but not in 
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the her2-positives, hinting at some subgroup specificity (Fig S4B). Concerning different 
therapies, neither marker was a significant predictor of outcome in patients treated with 
anthracyclines and taxanes, while both markers significantly predicted outcome after 
anthracycline-based therapy that lacked taxanes (MUC17: DFS p<0.01, DSS p<0.04; PCNX: 
DFS p<0.04) (Fig S4C). Overall, we concluded that expression levels of MUC17 or PCNX1 
significantly predict survival after anthracycline-based chemotherapy in a range of breast 





NAC provides opportunities to characterise cancer cells that are relatively therapy resistant 
(cells that remain after therapy) or relatively sensitive to therapy (cells present before but not 
after therapy). However, assessment of these cells presents logistical and methodological 
challenges (11). One key issue is obtaining the matched cancer cells pre- and post-NAC that 
are necessary to allow comparison. Diagnostic biopsies are taken from women with breast 
symptoms, at which time it is not even possible to identify those with cancer, let alone the 
small minority who go on to receive NAC; therefore, it is impractical to collect research 
material at this point. Moreover, the NAC treatment pathway does not normally include 
further pre-NAC tissue sampling opportunities. The result is that diagnostic biopsies are 
often the only practical pre-NAC tissue available, but unfortunately these are very small and 
FFPE-treated, which can limit down-stream analyses. By contrast, difficultly post-NAC is 
caused by relative lack of cancer cells within tissues rather than sizes of available tissue per 
se. Successful NAC reduces tumour size and cancer cellularity (31), therefore cancer cells 
can be comparatively scarce post-NAC, within an abnormal fibrotic stroma (32). This last 
issue explains why we felt it was necessary to perform LCM of cancer cells, and thereby 
avoid wasteful sequencing of normal DNA derived from stromal cells and potentially-flawed 
comparisons of variant prevalence between cancer cell-rich (pre-NAC) and cancer cell-poor 
(post-NAC) samples. Concerns regarding the representative nature of these samples remain 
even after LCM. Diagnostic biopsies sample only a small proportion of the total tumour 
volume, and it is unlikely they contain all the tumour genetic diversity, while even use of 
resection samples, which could contain all the genetic diversity, is limited by the proportion 
of tumour cells analysed (33). Despite all these issues, studies have been published 
comparing characteristics of breast tumours pre- and post-NAC at the levels of protein (13), 
transcript (14,25), and genome (25,34). To our knowledge, our study is the first to examine 
whole exome data pre- and post-NAC, while employing LCM in this context to give 
improvements in the accuracy of assessment of changes in mutant allele frequency. 
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Nevertheless, there are two highly-related previous studies. Balko et al used targeted 
sequencing of selected exons of 196 cancer-related genes to investigate changes in variants 
representation in 20 triple negative breast cancers, treated with a range of different NAC 
regimens (24). The authors found a minority of variants to be present in both matched 
samples, which mirrors our findings (Fig 1), while overall they found variants in cell-cycle 
regulators and PI3K/mTOR pathway genes to be enriched post-NAC. Recently, Kim et al 
published the first study to investigate matched pre- and post-NAC exomes in breast cancer, 
in which they also examined 20 triple negative breast cancers (25). The difficulty of low 
tumour cellularity was exemplified in this work, as some post-treatment samples were 
assessed by histopathology as containing as little as 10%, or even 0% tumour cells. Like our 
study, the key findings show that therapy drives expansion of resistant clones, or contraction 
of sensitive clones, in the background of an overall decrease in variants. Interestingly, in 
both studies, the authors tried to adjust their mutant allele frequencies for differences in 
tumour cellularity to allow comparison between matched samples, which represents an 
alternative approach to LCM, although at the cost of using 90% or more of read depth on 
normal genome. 
 
In accordance with the published literature describing profound heterogeneity in somatic 
variants between breast cancers (22), we found no variants in common between any of our 
6 tumours, despite our attempt to minimise variation in histopathological features of the 
group (Table S1). However, there was commonality between patients in genes hosting 
variants at relatively low mutant allele frequencies and in their distribution between pre- or 
post-NAC samples, allowing us to identify MUC17 and PCNX1 as candidate regulators of 
chemoresponse (Table 1). It is interesting to note that somatic variants in these genes have 
not been identified previously as candidate driver mutations in the wealth of cancer genome 
studies available in breast cancer (35); this may relate to the paired pre- and post-treatment 
design of our study, which provides a strategy to prioritise rare sub-clonal variants for further 
analysis based on a change in representation after treatment, whereas important rare sub-
clonal variants can be lost in the noise in a single time-point study. Furthermore, MUC17 and 
PCNX1 demonstrated roles in defining chemoresponse in vitro (Fig 2) and in two separate 
cohorts of patient samples (Fig 4) that were compatible with the selection acting on the 
somatic variants identified in our initial cohort, allowing us to propose these genes as 
functional mediators of, and biomarkers for chemotherapy response. For both genes, this 
represents a novel finding.  
 
MUC17 belongs to the mucin family of O-glycosylated, high molecular weight, glycoproteins 
that contribute to mucus at mucosal surfaces (36). Little is known about MUC17 function, 
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however it is relevant to note that up-regulation of several mucins, most compellingly MUC1 
and MUC4, has been shown to induce chemoresistance (37), potentially by forming a 
physical barrier reducing tumoural drug concentrations, or by inhibiting apoptosis. In 
pancreatic and cervical cancer cells, MUC1 has also been linked to up-regulation of the 
xenobiotic transporter ABCB1 (38,39), which is associated with chemoresistance (29). The 
work presented here is the first to identify and test a role for MUC17 in chemoresistance, 
and to investigate a potential mechanism: regulation of ABCB1 and ABCC1, similarly to 
MUC1. Interestingly, MUC17 somatic mutations in cancer have very recently been 
investigated in two seemingly conflicting studies: MUC17 was defined as a recurrently 
mutated gene in multiple cancer types (although specifically not in breast) (40) while, by 
contrast, MUC17 was identified as having significantly fewer somatic mutations than 
expected (41), suggesting wild type function was required in ‘successful’ cancer cells.  Our 
interpretation of this conflict is that the depth of tumour cell sequencing, as highlighted 
above, may be critical for detecting MUC17 mutations, which were in only ~18% of the 
tumour cells at most in our data (Table 1), and this was in the context that we had purified 
the cancer genomes from the normal genomes of stromal cells that can comprise a large 
majority in many tumour samples. Even less is known about human PCNX1 (pecanex 
homolog 1) and its functions. The Drosophila protein, pecanex, is a positive regulator of 
Notch-signalling in neurogenic tissues (42). However, expression of the mammalian 
homolog, PCNX1, could not be detected in neuronal tissues, and a potential role was 
inferred in spermatogenesis because of expression in testis (43). The link with Notch is 
intriguing in the context of our study, since Notch-signalling has also been implicated as a 
positive regulator of chemoresistance (18). However, this relationship can not explain how 
reduced/low PCNX1 could associate with chemoresistance, since reduced PCNX1 function 
would potentially inhibit Notch-signalling and thereby act against Notch-induced 
chemoresistance. The only manuscript describing a cancer-related function for PCNX1 
shows it to be a positive regulator of the oncoprotein Skp2 in lung cancer (44). Interestingly, 
this function is independent of PCNX1 protein, since the transcripts act as a competitive 
endogenous RNAs that derepresses Skp2 expression by sequestering inhibitory 
microRNAs. Skp2 has itself been reported as a chemoresistance mediator (45), but again 
this relationship is the reverse of that which would explain our findings for PCNX1, therefore 
chemoresistance mechanisms directly downstream of PCNX1 remain unknown. In the case 
of PCNX1, where variants were identified only after chemotherapy, it is interesting to 
speculate about whether these variants were present pre-therapy below the detection level, 
or whether they were actually caused by chemotherapy itself and then selected through 
relative resistance. Our assessment is that it is most likely they were previously present. 
This is based on the abilities of the chemotherapy agents (epirubicin/cyclophosphamide) to 
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induce different classes of mutations. Both PCNX1 variants detected were small deletions, 
while cyclophosphamide and doxorubicin (an anthracycline closely related to epirubicin) 
have been shown not to induce somatic deletions at levels above background (46).   
 
In conclusion, we present genomics and expression data from 3 separate cohorts to show 
that MUC17 and PCNX1 are potential markers for chemotherapy stratification. In addition, 
since mucins are well-established therapeutic targets in cancer (47), MUC17 presents an 
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Table 1. Somatic variants in MUC17 or PCNX1 that changed representation after NAC were 
identified in 3 out of 6 patients.  Details included are: chromosomal position in the reference 
genome, mutant allele frequency (relative to 1), mutant read depth, and effects of variants on 
encoded proteins in terms of primary protein sequence and predictions of functional impact 
(from SnpEff, Polyphen, and SIFT). Note: SIFT (Sorting Intolerant from Tolerant) values 
represent predicted functional impact on scale of 0-1, with 0 being the more damaging end 






































Lymph node positive 33 (62) 112 (37) 
ER positive 16 (30) 206 (68) 
her2 positive 38 (72)  66 (22)  
Chemotherapy: anthracycline-based 
- without taxanes 
- with taxanes 











Table 2. Clinico-pathological details of the neoadjuvant and adjuvant cohorts. 
Note: ER and her2 status was unknown in 5 neoadjuvant cases and her2 status was 







Figure 1. Numbers and distribution of somatic variants identified in breast cancers pre- and 
post-NAC. Venn diagrams illustrate the numbers of somatic variants identified in the cancer 
cells of 6 numbered breast tumours. Variants were identified pre-NAC (left) and post-NAC 
(right), with those shared between these time-points within the intersect. 
 
Figure 2. MUC17 and PCNX1 regulate chemoresponse in vitro. MCF7 cells were 
transfected with siRNA targeted against MUC17 (left) or PCNX1 (right), or with non-targeting 
siRNA control.  A) MUC17 (left) or PCNX1 (right) expression was assessed by qPCR 48 to 
96h post-transfection. Error bars represent SEM of technical replicates. B) Cells were 
treated with doses of epirubicin 24h after transfection, and relative cell survival was 
determined a further 24, 48, or 72h later using MTT assays. Error bars represent SEM of 3 
fully-independent experiments. Overall significance between targeted siRNA vs control was 
analysed using 2-way ANOVA tests. C) Cells were treated with doses of epirubicin 24h after 
transfection, before relative cell survival was determined using clonogenic survival assays.  
Error bars represent SEM of 3 fully-independent experiments. *indicates significant 
differences at specific doses (p<0.05 Mann Whitney test). Overall significance between 
targeted siRNA vs control was analysed using 2-way ANOVA tests.   
 
Figure 3. MUC17 and PCNX1 are variably expressed across different breast cancers. 
Expression levels of MUC17 or PCNX1 were determined by immunohistochemistry in the 
cancer cells of breast cancer resections from cohorts of patients treated with neoadjuvant 
(n=53) or adjuvant (n=303) chemotherapy. A) Representative images of staining are shown 
for MUC17 (left) and PCNX1 (right). Individual tumour cores were scored to quantify 
expression on a scale of 0-3 (MUC17) or 0-7 (PCNX1). For MUC17, examples of moderate 
(scored as 2) and strong (scored as 3) staining are shown. For PCNX1, examples of 
moderate staining (scored as 2) in 25-75% of tumour cells (scored as 3; total 5), and of 
strong staining (3) in >75% of tumour cells (4; total 7) are shown. B) Histograms showing 
score distributions across the neoadjuvant and adjuvant cohorts. Case scores were 
determined from means of all cores scored for that case, and were rounded to the closest 
whole integer in these histograms.   
 
Figure 4. Expression of MUC17 and PCNX1 predict survival after chemotherapy. 
Expression levels of MUC17 or PCNX1 were determined by immunohistochemistry in the 
cancer cells of breast cancer resections from cohorts of patients treated with neoadjuvant 
(A; n=53) or adjuvant (B and C; n=303) chemotherapy. Expression levels were dichotomised 
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objectively into low or high groups using ROC analyses. Kaplan-Meier analyses were 
performed comparing disease free survival (DFS) or disease specific survival (DSS) in two 
groups. A and B) Analyses compare groups with low or high expression of MUC17 (left) or of 
PCNX1 (right). C) Analyses compare the group with high MUC17 expression and low 
PCNX1 expression (high M/low P) to the remainder of the cohort (“rest”) (left), or the group 
with low MUC17 expression and high PCNX1 expression (low M/high P) to the rest (right). 























Figure 4.  
